Research programme: infectious diseases therapeutic vaccines - Vakzine Project Management
Alternative Names: DB; MSP-1/HD-1 adjuvant; rBCGΔUreC:Hly; VPM 2001Latest Information Update: 28 Jul 2018
Price :
$50 *
At a glance
- Originator Vakzine Projekt Management
- Developer Rhein Biotech; Vakzine Projekt Management
- Class Bacterial vaccines; Tuberculosis vaccines; Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cytomegalovirus infections
- Discontinued Malaria; Tuberculosis
Most Recent Events
- 28 Jul 2018 No recent reports of development identified for preclinical development in Cytomegalovirus infections in Germany
- 29 Jul 2016 Preclinical development is ongoing for Cytomegalovirus infections in Germany (Vakzine Projekt Management pipeline, July 2016)
- 29 Jul 2016 Discontinued - Preclinical for Malaria in Germany (IM)